Chang Jiang 姜畅
@ChangJiangLab
Assistant member @MoffittNews studying redox biology, cancer metabolism and mitochondria.
The Jiang Lab @MoffittNews is hiring! We're looking for a motivated postdoc to study selenium metabolism in NSCLC. Apply now 👉 …cancer-center-careers.hctsportals.com/jobs/1740466-c…
Happy Friday! @LyssiotisLab and I had a fun time hyping up our favorite metabolite Uridine as the Metabolite of the Month in @CellCellPress! We hope you enjoy this quick read! cell.com/trends/endocri…
Congratulations! Stan! Well deserved! 👍
Grateful to @NIH for being awarded prestigious K99/R00 Pathway to Independence award. Big thanks to @lab_gomes and @MoffittNews for the opportunity to advance my research in a supportive environment. Excited for what’s ahead!
Big day for the David lab! 🎉 Our @MolecularCell paper is out today- huge congrats to first authors @IfeAkano & Jake Hebert for leading this beautiful study uncovering SMARCA3 as a novel H3 E3 ligase that shapes heterochromatin regulation in colorectal cancer 🤩
Online Now: The SWI/SNF-related protein SMARCA3 is a histone H3K23 ubiquitin ligase that regulates H3K9me3 in cancer dlvr.it/TLz0Lw
Congratulations!
Proud to share @niseto’s (new PI @TheCrick) paper: As a postdoc (@CSHL/@HopkinsMedicine), he found #NETs in necrotic tumors—I shrugged. But he looked closer: NETs block tumor vessel perfusion, causing necrosis, hypoxia, EMT & #Metastasis. nature.com/articles/s4158… @JHU_BDP @Nature
I was honored for Dr. Jiang, Assistant Member in the Dept of Molecular Oncology in the Division of Basic Science @MoffittNews , to share her exciting work on metabolic pathways driven by NRF2 in lung cancer! #MoffittAACR25 #AACR2025
During #AACR25, Chang Jiang, PhD, (@ChangJiangLab) joins Elsa Flores, PhD, (@LabElsaFlores), to share insights into NRF2 expression in non-small cell lung cancer. #MoffittAACR25
Happy to have contributed in a small way to this very cool study from Jim Wells lab, led by Fangzhu Zhao. They developed low-density lipoprotein receptor-targeting chimeras (LIPTACs) to promote induced extracellular protein degradation & ADC delivery. 👏 biorxiv.org/content/10.110…
👀 forward to it! Thank you @LabElsaFlores for all the hard work!
I had the privilege of showing off the progress of the Moffitt Discovery and Innovation Center at SPEROS FL to a group of pioneering faculty. It’s been a real labor of love! Thank you to TKD, Whiting Turner, and Hammes for bringing the vision to life! Can’t wait to make new…
Another preprint from our group, this one describing how the transcription factor FRA1 promoted #melanoma metastasis
FRA1 drives melanoma metastasis through an actionable transcriptional network biorxiv.org/content/10.110… #biorxiv_cancer
Had a great time today touring the future Moffitt Discovery & Innovation Center! Excited for this new chapter for our Basic Science Division @MoffittNews lead by the amazing @LabElsaFlores
Happy to see our highlight out in @CurrentBiology discussing new findings related to NADH and FSP1 compartmentalization in ferroptosis. Lead by two terrific postdocs @AMegarioti and Kirandeep Deol! 🤩 cell.com/current-biolog…
I'm excited to share the lab’s new paper on PDAC-associated cachexia on bioRxiv today, led by star postdoc @Nikita2106 Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose de novo lipogenesis A 🧵 below, if you're interested... biorxiv.org/content/10.110…
Preprint alert: check out our new genetically engineered mouse model of uveal melanoma, which recapitulates many aspects of the human disease including phenotypic plasticity
A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma biorxiv.org/content/10.110… #biorxiv_cancer
🚨 New meeting this fall in Brussels! 🚨 Cutting-edge science, amazing colleagues, & a RARE career development workshop for trainees-covering pharma, consulting, writing, start-ups & more 🤩 #epigenetics2025 Registration is open!! @epicypher @FuksLab xcellsconferences.com/epigenetics2025
Thrilled this paper is out! We solved the first cocrystal structure of FSP1 with an inhibitor (FSEN1), providing mechanistic insight & a foundation for medchem. Led by @AMegarioti & Sitao Zhang. A terrific collaboration with Da Jia. Brief Tweetorial! 1/9 pnas.org/doi/10.1073/pn…
We don't just deliver innovative cancer treatments, we invent them. Moffitt is proud to be named among Tampa Bay’s top patent holders, driving breakthroughs that shape the future of cancer care in Florida and beyond. Read more: bit.ly/3YL7lI5 @TBBJnewsroom…
Thrilled to share that my main postdoctoral project in Josh Rabinowitz’s lab is out today at @CellCellPress! We found an unexpected, diet- and microbiota-dependent mechanism that affects the anticancer activity of PI3K inhibitors. Thread below👇
It is an honor to be recognized by the Florida Inventors Hall of Fame. I look forward to continuing to work with my colleagues to develop tools and models to help advance cancer discoveries.
x.com/i/article/1924…
My two NIH cancer research grants were terminated today. One involving breast cancer prevention is an “outstanding investigator award” and had received a perfect score by reviewers. How does ending lifesaving cancer research make Americans healthier? @harvardmed @aacr
"Cancer cells don’t quickly adapt or rewire this copper dependency, which creates a therapeutic window. By introducing a copper chelator, we can dampen the MAPK signaling that tumors rely on for growth." —@bradylabupenn, @jbiolchem associate editor ow.ly/hVCN50VQpfS